SELLAS Life Sciences Group, Inc. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים SLS

This price evolution chart on GURU.Markets for SELLAS Life Sciences (SLS) shows an EPS of 34.70. The survival of this immunotherapy developer currently depends on the results of final leukemia tests amid nearly depleted capital. Business success relies on the efficacy of acute myeloid leukemia treatment and access to funding. Growth is driven by orphan drug privileges and the trial results of the galinpepimut-S vaccine.

The market views SELLAS Life Sciences (SLS) as a high-risk asset with breakthrough potential in leukemia therapy. This metric measures the dynamics of net income per share over a trailing twelve-month period, allowing for a real-time assessment of the business's profitability trends. By analyzing the annual percentage change in earnings per share (TTM), investors can see the impact of vaccine costs on capitalization. For the biotech sector, this indicator serves as a marker of financial stability amidst a constant search for investment.